RT Journal Article
T1 Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm.
A1 Formiga, Francesc
A1 Chivite, David
A1 Nuñez, Julio
A1 Moreno Garcia, Ma Carmen
A1 Manzano, Luis
A1 Arevalo-Lorido, Jose Carlos
A1 Cerqueiro, Jose Manuel
A1 Garcia Campos, Alvaro
A1 Trullas, Joan Carles
A1 Montero-Perez-Barquero, Manuel
K1 All-cause mortality
K1 Beta-adrenergic receptor blockers
K1 Bloqueadores dos recetores β-adrenérgicos
K1 Fração de ejeção preservada
K1 Heart failure
K1 Heart failure readmission
K1 Insuficiência cardíaca
K1 Mortalidade global
K1 Preserved ejection fraction
K1 Reinternamento por insuficiência cardíaca
AB Beta-adrenergic receptor blockers (beta-blockers) are frequently used for patients with heart failure (HF) with preserved ejection fraction (HFpEF), although evidence-based recommendations for this indication are still lacking. Our goal was to assess which clinical factors are associated with the prescription of beta-blockers in patients discharged after an episode of HFpEF decompensation, and the clinical outcomes of these patients. We assessed 1078 patients with HFpEF and in sinus rhythm who had experienced an acute HF episode to explore whether prescription of beta-blockers on discharge was associated with one-year all-cause mortality or the composite endpoint of one-year all-cause death or HF readmission. We also examined the clinical factors associated with beta-blocker discharge prescription for such patients. At discharge, 531 (49.3%) patients were on beta-blocker therapy. Patients on beta-blockers more often had a prior diagnosis of hypertension and more comorbidity (including ischemic heart disease) and a better functional status, but less often a prior diagnosis of chronic obstructive pulmonary disease. These patients had a lower heart rate on admission and more often used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors and loop diuretics. One year after the index admission, 161 patients (15%) had died and 314 (29%) had experienced the composite endpoint. After multivariate adjustment, beta-blocker prescription was not associated with either all-cause mortality (HR=0.83 [95% CI 0.61-1.13]; p=0.236) or the composite endpoint (HR=0.98 [95% CI 0.79-1.23]; p=0.882). In patients with HFpEF in sinus rhythm, beta-blocker use was not related to one-year mortality or mortality plus HF readmission.
PB Elsevier
YR 2022
FD 2022-06-02
LK http://hdl.handle.net/10668/22497
UL http://hdl.handle.net/10668/22497
LA en
LA pt
NO Formiga F, Chivite D, Nuñez J, Moreno García MC, Manzano L, Arévalo-Lorido JC,  et al. Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm. Rev Port Cardiol. 2022 Oct;41(10):853-861. English, Portuguese
DS RISalud
RD Apr 11, 2025